Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Agenus, Gilead Milestone Triggers $7.5M Payment | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Agenus, Gilead Milestone Triggers $7.5M Payment

FDA acceptance of IND filing for AGEN237 represents the second milestone in Gilead partnership achieved in 2019

By: Cassandra Gervolino

Agenus Inc. announced that the FDA has accepted the company’s IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5 million. Agenus is eligible to receive additional milestone payments this year and beyond.
 
“This IND clearance underscores our continued commitment to delivering novel and best-in-class therapies to patients with cancer with the utmost urgency,” said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. “AGEN2373 has unique binding properties and is designed to mitigate the toxicity observed with competitor molecules; we believe that this molecule has great potential for patients with cancer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics